Dr. Mark Santillan
  • Dr. Mark Santillan
  • Professor, Department of Obstetrics and Gynecology
    University of Iowa Carver College of Medicine

Mark Santillan is a Professor in the Department of OB-GYN and Molecular Medicine at the University of Iowa. As a Maternal Fetal Medicine specialist his clinical and research interests are in hypertensive disorders in pregnancy and the immunology of pregnancy. His lab is particularly interested in the early mechanisms of maternal health during pregnancy and the short and life-life health effects to the mother and child.

He has extensive national and international experience (AHA PREDICTV, NIH iELEVATE, NIH RELIANCE) in clinical cohort development from diverse sources, clinical data harmonization, and central data and biosample management. He serves as the Clinical Translational Core Co-director for the NIH P50 funded Iowa Hawkeye Intellectual and Developmental Disabilities Research Center (IDDRC) as well as the Associate Director for the Women’s Health Initiative for the NIH funded Iowa Institute for Clinical and Translational Science (ICTS).

Dr. Santillan is also a member of the steering committee of CoLab, an international research collaborative of over 40 sites that aims at sharing expertise, clinical data, and biosamples to help accelerate research in lifelong perinatal disease. He also serves on American Heart Association/American College of Cardiology committees to help redefine hypertension in women and provider education in women’s cardiovascular disease. He has had various national scientific and research leadership positions in the Society for Maternal Fetal Medicine, American Heart Association, and American Physiological Society.

He serves as a regular member of the Pregnancy-Neonatology Study Section for the National Institutes of Health and serves on the NIH Maternal Health Innovation Workgroup. His expertise in Maternal-Fetal Medicine, clinical cohort management, basic/translational research, and basic mechanisms of perinatal disease are focused on investigating perinatal disease at the basic, translational, and clinical levels.

Back to Team